title: Serial optical coherence tomography-based observation of strut coverage on drug-eluting stent crossing side-branch vessels.
abstract: BACKGROUND
  Serial changes in strut coverage of drug-eluting stents (DESs), which are placed across side-branch vessels, remain unclear.
  
  
  METHODS
  The changes in strut coverage of DESs crossing side-branch vessels (size ≥2.0 mm) were serially evaluated by optical coherence tomography (OCT) in 30 patients at 9 months and 2 years after the index DES implantation. DESs were paclitaxel-eluting stents (PESs), sirolimus-eluting stents (SESs), and zotarolimus-eluting stents (ZESs), each in 10 patients. Measured neointimal hyperplasia (NIH) thickness of 0 μm on OCT was defined as an uncovered strut.
  
  
  RESULTS
  The percentage of uncovered side-branch struts significantly decreased from 55.7 ± 39.9% to 36.6 ± 32.0% (P<.0001) on serial follow-up: PES, 93.4 ± 10.5% to 67.6 ± 24.2%, P=.018; SES, 47.5 ± 34.4% to 29.6 ± 24.1%, P=.036; and ZES, 26.2 ± 34.8% to 12.4 ± 19.0%, P=.028. Among covered side-branch struts, the overall percentage of struts with NIH thickness more than 30 μm significantly increased from 36.3 ± 37.4% to 51.0 ± 36.0% (P<.0001). However, compared to other DES types, a significant increase in relatively thin NIH (0 to 30 μm) was observed in PESs (1.6 ± 3.4% to 17.4 ± 16.0%; P=.018).
  
  
  CONCLUSIONS
  Serial follow-up OCT examination showed a significant decrease in the percentage of uncovered side-branch struts, and the coverage pattern differed with DES type.
authors.affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, South Korea.
authors.forename: Seung-Yul
authors.initials: SY
authors.lastname: Lee
authors.forename: Jung-Sun
authors.initials: JS
authors.lastname: Kim
authors.forename: Dong-Ho
authors.initials: DH
authors.lastname: Shin
authors.forename: Byeong-Keuk
authors.initials: BK
authors.lastname: Kim
authors.forename: Young-Guk
authors.initials: YG
authors.lastname: Ko
authors.forename: Donghoon
authors.initials: D
authors.lastname: Choi
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Myeong-Ki
authors.initials: MK
authors.lastname: Hong
mesh_terms: D000368:Aged; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000473:pathology; D017239:Paclitaxel; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods*; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*
chemical_list: C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus